JP2019505558A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019505558A5 JP2019505558A5 JP2018544154A JP2018544154A JP2019505558A5 JP 2019505558 A5 JP2019505558 A5 JP 2019505558A5 JP 2018544154 A JP2018544154 A JP 2018544154A JP 2018544154 A JP2018544154 A JP 2018544154A JP 2019505558 A5 JP2019505558 A5 JP 2019505558A5
- Authority
- JP
- Japan
- Prior art keywords
- pyrazolo
- dihydro
- oxazine
- carboxamide
- cyclopropyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003839 salts Chemical class 0.000 claims description 71
- 150000001875 compounds Chemical class 0.000 claims description 55
- -1 cyano, hydroxy Chemical group 0.000 claims description 50
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 29
- 125000001072 heteroaryl group Chemical group 0.000 claims description 28
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 24
- 229910052736 halogen Inorganic materials 0.000 claims description 20
- 150000002367 halogens Chemical class 0.000 claims description 20
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 18
- 229910052739 hydrogen Inorganic materials 0.000 claims description 16
- 239000001257 hydrogen Substances 0.000 claims description 16
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 14
- JROPBYGZSRBHDV-UHFFFAOYSA-N oxazine-2-carboxamide Chemical compound NC(=O)N1OC=CC=C1 JROPBYGZSRBHDV-UHFFFAOYSA-N 0.000 claims description 12
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 9
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims description 8
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 8
- 125000001153 fluoro group Chemical group F* 0.000 claims description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 8
- 229910052757 nitrogen Inorganic materials 0.000 claims description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 8
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 8
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 8
- 125000000217 alkyl group Chemical group 0.000 claims description 7
- 150000002431 hydrogen Chemical class 0.000 claims description 7
- 125000003118 aryl group Chemical group 0.000 claims description 6
- 125000002393 azetidinyl group Chemical group 0.000 claims description 6
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 6
- 125000004076 pyridyl group Chemical group 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 5
- MJHYQMWSWMXYQH-UHFFFAOYSA-N 3-(4-cyano-5-fluoro-2-methylphenyl)-N-cyclopropyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide Chemical compound C(#N)C1=CC(=C(C=C1F)C=1C(=NN2C=1OCCC2)C(=O)NC1CC1)C MJHYQMWSWMXYQH-UHFFFAOYSA-N 0.000 claims description 4
- HXVNESZNUYSKMT-UHFFFAOYSA-N 4-[2-(azetidine-1-carbonyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-yl]-2-fluoro-5-methylbenzonitrile Chemical compound Cc1cc(C#N)c(F)cc1-c1c2OCCCn2nc1C(=O)N1CCC1 HXVNESZNUYSKMT-UHFFFAOYSA-N 0.000 claims description 4
- GRFHQTKEAOBDST-NSHDSACASA-N ClC1=CC(=C(C=C1)C=1C(=NN2C=1OC[C@H](C2)F)C(=O)NC1CC1)C Chemical compound ClC1=CC(=C(C=C1)C=1C(=NN2C=1OC[C@H](C2)F)C(=O)NC1CC1)C GRFHQTKEAOBDST-NSHDSACASA-N 0.000 claims description 4
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 4
- 125000001786 isothiazolyl group Chemical group 0.000 claims description 4
- 125000004043 oxo group Chemical group O=* 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims description 4
- 208000011117 substance-related disease Diseases 0.000 claims description 4
- NXQIEDDZYQXLGS-LLVKDONJSA-N (6R)-3-(4-chlorophenyl)-N-cyclopropyl-6-fluoro-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide Chemical compound F[C@H]1COc2c(c(nn2C1)C(=O)NC1CC1)-c1ccc(Cl)cc1 NXQIEDDZYQXLGS-LLVKDONJSA-N 0.000 claims description 2
- QMOPFHQOZKALTC-ZETCQYMHSA-N (6S)-3-(4-chloro-2,5-difluorophenyl)-N-cyclopropyl-6-fluoro-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide Chemical compound ClC1=CC(=C(C=C1F)C=1C(=NN2C=1OC[C@H](C2)F)C(=O)NC1CC1)F QMOPFHQOZKALTC-ZETCQYMHSA-N 0.000 claims description 2
- NXQIEDDZYQXLGS-NSHDSACASA-N (6S)-3-(4-chlorophenyl)-N-cyclopropyl-6-fluoro-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide Chemical compound F[C@@H]1COc2c(c(nn2C1)C(=O)NC1CC1)-c1ccc(Cl)cc1 NXQIEDDZYQXLGS-NSHDSACASA-N 0.000 claims description 2
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims description 2
- 125000004502 1,2,3-oxadiazolyl group Chemical group 0.000 claims description 2
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 claims description 2
- 125000004506 1,2,5-oxadiazolyl group Chemical group 0.000 claims description 2
- 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 claims description 2
- PHRSCPGZAINQTD-UHFFFAOYSA-N 2H-1,3-oxazine-2-carboxamide Chemical compound O1C(N=CC=C1)C(=O)N PHRSCPGZAINQTD-UHFFFAOYSA-N 0.000 claims description 2
- LGFLTCBFNXDCLY-UHFFFAOYSA-N 3-(3-chloro-4-fluorophenyl)-N-cyclopropyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide Chemical compound Fc1ccc(cc1Cl)-c1c2OCCCn2nc1C(=O)NC1CC1 LGFLTCBFNXDCLY-UHFFFAOYSA-N 0.000 claims description 2
- GBWMEFKBLUNZIM-UHFFFAOYSA-N 3-(3-chlorophenyl)-N-cyclopropyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide Chemical compound Clc1cccc(c1)-c1c2OCCCn2nc1C(=O)NC1CC1 GBWMEFKBLUNZIM-UHFFFAOYSA-N 0.000 claims description 2
- FGOAWTXGIORNAM-UHFFFAOYSA-N 3-(4-chloro-2,3-difluorophenyl)-N-cyclopropyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide Chemical compound Fc1c(Cl)ccc(-c2c3OCCCn3nc2C(=O)NC2CC2)c1F FGOAWTXGIORNAM-UHFFFAOYSA-N 0.000 claims description 2
- WYSBJUKHVQZOHC-UHFFFAOYSA-N 3-(4-chloro-2,5-difluorophenyl)-N-cyclopropyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide Chemical compound Fc1cc(-c2c3OCCCn3nc2C(=O)NC2CC2)c(F)cc1Cl WYSBJUKHVQZOHC-UHFFFAOYSA-N 0.000 claims description 2
- MYPOVEUFNMJGML-UHFFFAOYSA-N 3-(4-chloro-2,5-difluorophenyl)-N-ethyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide Chemical compound CCNC(=O)c1nn2CCCOc2c1-c1cc(F)c(Cl)cc1F MYPOVEUFNMJGML-UHFFFAOYSA-N 0.000 claims description 2
- IFCNLIRUYVNPKA-UHFFFAOYSA-N 3-(4-chloro-2-fluorophenyl)-N-cyclopropyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide Chemical compound Fc1cc(Cl)ccc1-c1c2OCCCn2nc1C(=O)NC1CC1 IFCNLIRUYVNPKA-UHFFFAOYSA-N 0.000 claims description 2
- RQKJDWFZSBVQSW-UHFFFAOYSA-N 3-(4-chloro-2-methylphenyl)-N-cyclopropyl-6,6-difluoro-5,7-dihydropyrazolo[5,1-b][1,3]oxazine-2-carboxamide Chemical compound Cc1cc(Cl)ccc1-c1c2OCC(F)(F)Cn2nc1C(=O)NC1CC1 RQKJDWFZSBVQSW-UHFFFAOYSA-N 0.000 claims description 2
- KXLPTRRQYABNIU-UHFFFAOYSA-N 3-(4-chloro-2-methylphenyl)-N-cyclopropyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide Chemical compound Cc1cc(Cl)ccc1-c1c2OCCCn2nc1C(=O)NC1CC1 KXLPTRRQYABNIU-UHFFFAOYSA-N 0.000 claims description 2
- GRFHQTKEAOBDST-UHFFFAOYSA-N 3-(4-chloro-2-methylphenyl)-N-cyclopropyl-6-fluoro-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide Chemical compound Cc1cc(Cl)ccc1-c1c(nn2CC(F)COc12)C(=O)NC1CC1 GRFHQTKEAOBDST-UHFFFAOYSA-N 0.000 claims description 2
- ZDSSYIMMEPTDEO-UHFFFAOYSA-N 3-(4-chloro-3,5-difluorophenyl)-N-cyclopropyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide Chemical compound Fc1cc(cc(F)c1Cl)-c1c2OCCCn2nc1C(=O)NC1CC1 ZDSSYIMMEPTDEO-UHFFFAOYSA-N 0.000 claims description 2
- TWKMZYIUVKFGDK-UHFFFAOYSA-N 3-(4-chloro-3-fluorophenyl)-N-cyclopropyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide Chemical compound Fc1cc(ccc1Cl)-c1c2OCCCn2nc1C(=O)NC1CC1 TWKMZYIUVKFGDK-UHFFFAOYSA-N 0.000 claims description 2
- MKFKTQOJJMIDOC-UHFFFAOYSA-N 3-(4-chloro-3-fluorophenyl)-N-cyclopropyl-6-fluoro-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide Chemical compound FC1COc2c(c(nn2C1)C(=O)NC1CC1)-c1ccc(Cl)c(F)c1 MKFKTQOJJMIDOC-UHFFFAOYSA-N 0.000 claims description 2
- KPTCNORYAGZPTM-UHFFFAOYSA-N 3-(4-chloro-3-fluorophenyl)-N-methyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide Chemical compound CNC(=O)c1nn2CCCOc2c1-c1ccc(Cl)c(F)c1 KPTCNORYAGZPTM-UHFFFAOYSA-N 0.000 claims description 2
- SPFPGSNCBFECSG-UHFFFAOYSA-N 3-(4-chloro-3-fluorophenyl)-N-propan-2-yl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide Chemical compound CC(C)NC(=O)c1nn2CCCOc2c1-c1ccc(Cl)c(F)c1 SPFPGSNCBFECSG-UHFFFAOYSA-N 0.000 claims description 2
- AIIYPFJZLRJGEL-UHFFFAOYSA-N 3-(4-chloro-5-fluoro-2-methylphenyl)-N-cyclopropyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide Chemical compound Cc1cc(Cl)c(F)cc1-c1c2OCCCn2nc1C(=O)NC1CC1 AIIYPFJZLRJGEL-UHFFFAOYSA-N 0.000 claims description 2
- WYVVCFNADZMHEN-UHFFFAOYSA-N 3-(4-chloro-5-fluoro-2-methylphenyl)-N-ethyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide Chemical compound CCNC(=O)c1nn2CCCOc2c1-c1cc(F)c(Cl)cc1C WYVVCFNADZMHEN-UHFFFAOYSA-N 0.000 claims description 2
- XWLDNGLNMIBYMP-UHFFFAOYSA-N 3-(4-chloro-5-fluoro-2-methylphenyl)-N-methyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide Chemical compound CNC(=O)c1nn2CCCOc2c1-c1cc(F)c(Cl)cc1C XWLDNGLNMIBYMP-UHFFFAOYSA-N 0.000 claims description 2
- GYVJFOZZFFIUSZ-UHFFFAOYSA-N 3-(4-chlorophenyl)-N-cyclopropyl-5-methyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide Chemical compound CC1CCn2nc(C(=O)NC3CC3)c(c2O1)-c1ccc(Cl)cc1 GYVJFOZZFFIUSZ-UHFFFAOYSA-N 0.000 claims description 2
- NHVPCMGYIPONNR-UHFFFAOYSA-N 3-(4-chlorophenyl)-N-cyclopropyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide Chemical compound Clc1ccc(cc1)-c1c2OCCCn2nc1C(=O)NC1CC1 NHVPCMGYIPONNR-UHFFFAOYSA-N 0.000 claims description 2
- NXQIEDDZYQXLGS-UHFFFAOYSA-N 3-(4-chlorophenyl)-N-cyclopropyl-6-fluoro-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide Chemical compound FC1COc2c(c(nn2C1)C(=O)NC1CC1)-c1ccc(Cl)cc1 NXQIEDDZYQXLGS-UHFFFAOYSA-N 0.000 claims description 2
- ZTEOJNWIHZBBMB-UHFFFAOYSA-N 3-(4-chlorophenyl)-N-cyclopropyl-7-methyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide Chemical compound CC1CCOc2c(c(nn12)C(=O)NC1CC1)-c1ccc(Cl)cc1 ZTEOJNWIHZBBMB-UHFFFAOYSA-N 0.000 claims description 2
- KEZOJFATBPGWGR-UHFFFAOYSA-N 3-(4-cyano-2,5-difluorophenyl)-N-cyclopropyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide Chemical compound Fc1cc(-c2c3OCCCn3nc2C(=O)NC2CC2)c(F)cc1C#N KEZOJFATBPGWGR-UHFFFAOYSA-N 0.000 claims description 2
- MGICYBWWARAATG-UHFFFAOYSA-N 3-(4-cyano-2-methylphenyl)-N-cyclopropyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide Chemical compound Cc1cc(ccc1-c1c2OCCCn2nc1C(=O)NC1CC1)C#N MGICYBWWARAATG-UHFFFAOYSA-N 0.000 claims description 2
- RQCIGHZUMYJCCJ-UHFFFAOYSA-N 3-(4-cyano-3-fluorophenyl)-N-cyclopropyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide Chemical compound C(#N)C1=C(C=C(C=C1)C=1C(=NN2C=1OCCC2)C(=O)NC1CC1)F RQCIGHZUMYJCCJ-UHFFFAOYSA-N 0.000 claims description 2
- CICKNGAWODWCEX-UHFFFAOYSA-N 3-(4-cyano-5-fluoro-2-methylphenyl)-N-cyclopropyl-6-fluoro-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide Chemical compound Cc1cc(C#N)c(F)cc1-c1c(nn2CC(F)COc12)C(=O)NC1CC1 CICKNGAWODWCEX-UHFFFAOYSA-N 0.000 claims description 2
- GWWNXYAZKUJVBF-UHFFFAOYSA-N 3-(4-cyano-5-fluoro-2-methylphenyl)-N-ethyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide Chemical compound CCNC(=O)c1nn2CCCOc2c1-c1cc(F)c(cc1C)C#N GWWNXYAZKUJVBF-UHFFFAOYSA-N 0.000 claims description 2
- QQMQNXMQOPTOHL-UHFFFAOYSA-N 3-(5-cyano-2-fluorophenyl)-N-cyclopropyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide Chemical compound Fc1ccc(cc1-c1c2OCCCn2nc1C(=O)NC1CC1)C#N QQMQNXMQOPTOHL-UHFFFAOYSA-N 0.000 claims description 2
- WAMLUDBFCUDTPT-UHFFFAOYSA-N 3-(6-cyanopyridin-3-yl)-N-cyclopropyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide Chemical compound O=C(NC1CC1)c1nn2CCCOc2c1-c1ccc(nc1)C#N WAMLUDBFCUDTPT-UHFFFAOYSA-N 0.000 claims description 2
- HIZORNOKOHJTBO-UHFFFAOYSA-N 4-[2-(azetidine-1-carbonyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-yl]-2,5-difluorobenzonitrile Chemical compound Fc1cc(-c2c3OCCCn3nc2C(=O)N2CCC2)c(F)cc1C#N HIZORNOKOHJTBO-UHFFFAOYSA-N 0.000 claims description 2
- JVQZYDGQUZXTDQ-UHFFFAOYSA-N 4-[2-(azetidine-1-carbonyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-yl]-2,6-difluorobenzonitrile Chemical compound Fc1cc(cc(F)c1C#N)-c1c2OCCCn2nc1C(=O)N1CCC1 JVQZYDGQUZXTDQ-UHFFFAOYSA-N 0.000 claims description 2
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 208000019901 Anxiety disease Diseases 0.000 claims description 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 2
- TUHZURBDZPBKQB-UHFFFAOYSA-N ClC1=CC=C(C=C1)C=1C(=NN2C=1OCC(C2)(F)F)C(=O)NC1CC1 Chemical compound ClC1=CC=C(C=C1)C=1C(=NN2C=1OCC(C2)(F)F)C(=O)NC1CC1 TUHZURBDZPBKQB-UHFFFAOYSA-N 0.000 claims description 2
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims description 2
- 101001098805 Homo sapiens cAMP-specific 3',5'-cyclic phosphodiesterase 4A Proteins 0.000 claims description 2
- 101000988424 Homo sapiens cAMP-specific 3',5'-cyclic phosphodiesterase 4B Proteins 0.000 claims description 2
- 101000988423 Homo sapiens cAMP-specific 3',5'-cyclic phosphodiesterase 4C Proteins 0.000 claims description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 2
- 206010061218 Inflammation Diseases 0.000 claims description 2
- XMTOCICLPIPODV-UHFFFAOYSA-N N-cyclopropyl-3-(3,4-dichlorophenyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide Chemical compound Clc1ccc(cc1Cl)-c1c2OCCCn2nc1C(=O)NC1CC1 XMTOCICLPIPODV-UHFFFAOYSA-N 0.000 claims description 2
- MYBATSJXBUMOOH-UHFFFAOYSA-N N-cyclopropyl-3-[2-(difluoromethoxy)pyridin-4-yl]-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide Chemical compound FC(F)Oc1cc(ccn1)-c1c(nn2CCCOc12)C(=O)NC1CC1 MYBATSJXBUMOOH-UHFFFAOYSA-N 0.000 claims description 2
- ONZFTFUFKHZXEF-UHFFFAOYSA-N N-cyclopropyl-3-pyrazolo[1,5-a]pyridin-6-yl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide Chemical compound O=C(NC1CC1)c1nn2CCCOc2c1-c1ccc2ccnn2c1 ONZFTFUFKHZXEF-UHFFFAOYSA-N 0.000 claims description 2
- 208000018737 Parkinson disease Diseases 0.000 claims description 2
- 102000001708 Protein Isoforms Human genes 0.000 claims description 2
- 108010029485 Protein Isoforms Proteins 0.000 claims description 2
- 208000006011 Stroke Diseases 0.000 claims description 2
- 125000003342 alkenyl group Chemical group 0.000 claims description 2
- 125000003545 alkoxy group Chemical group 0.000 claims description 2
- 125000004414 alkyl thio group Chemical group 0.000 claims description 2
- 125000000304 alkynyl group Chemical group 0.000 claims description 2
- 208000002205 allergic conjunctivitis Diseases 0.000 claims description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 2
- 230000036506 anxiety Effects 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 208000024998 atopic conjunctivitis Diseases 0.000 claims description 2
- OEWWVAVGPPIPRO-UHFFFAOYSA-N azetidin-1-yl-[3-(3,4-dichlorophenyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-2-yl]methanone Chemical compound Clc1ccc(cc1Cl)-c1c(nn2CCCOc12)C(=O)N1CCC1 OEWWVAVGPPIPRO-UHFFFAOYSA-N 0.000 claims description 2
- ARADJHAPDWYDIE-UHFFFAOYSA-N azetidin-1-yl-[3-(3,5-difluoro-4-methoxyphenyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-2-yl]methanone Chemical compound COc1c(F)cc(cc1F)-c1c2OCCCn2nc1C(=O)N1CCC1 ARADJHAPDWYDIE-UHFFFAOYSA-N 0.000 claims description 2
- HGOQXTQGKPHGEY-UHFFFAOYSA-N azetidin-1-yl-[3-(4-chloro-2,3-difluorophenyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-2-yl]methanone Chemical compound N1(CCC1)C(=O)C1=NN2C(OCCC2)=C1C1=C(C(=C(C=C1)Cl)F)F HGOQXTQGKPHGEY-UHFFFAOYSA-N 0.000 claims description 2
- LTQPXIUEDFTWNR-UHFFFAOYSA-N azetidin-1-yl-[3-(4-chloro-2,5-difluorophenyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-2-yl]methanone Chemical compound N1(CCC1)C(=O)C1=NN2C(OCCC2)=C1C1=C(C=C(C(=C1)F)Cl)F LTQPXIUEDFTWNR-UHFFFAOYSA-N 0.000 claims description 2
- AYWBPURWDSSBNA-UHFFFAOYSA-N azetidin-1-yl-[3-(4-chloro-2-fluorophenyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-2-yl]methanone Chemical compound Fc1cc(Cl)ccc1-c1c2OCCCn2nc1C(=O)N1CCC1 AYWBPURWDSSBNA-UHFFFAOYSA-N 0.000 claims description 2
- BLUWLSQGJDRYLP-UHFFFAOYSA-N azetidin-1-yl-[3-(4-chloro-2-methylphenyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-2-yl]methanone Chemical compound Cc1cc(Cl)ccc1-c1c2OCCCn2nc1C(=O)N1CCC1 BLUWLSQGJDRYLP-UHFFFAOYSA-N 0.000 claims description 2
- XUMPDYRHXWOEDT-UHFFFAOYSA-N azetidin-1-yl-[3-(4-chloro-3,5-difluorophenyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-2-yl]methanone Chemical compound Fc1cc(cc(F)c1Cl)-c1c2OCCCn2nc1C(=O)N1CCC1 XUMPDYRHXWOEDT-UHFFFAOYSA-N 0.000 claims description 2
- AQWXGANUJJZTGU-UHFFFAOYSA-N azetidin-1-yl-[3-(4-chloro-3-fluorophenyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-2-yl]methanone Chemical compound Fc1cc(ccc1Cl)-c1c2OCCCn2nc1C(=O)N1CCC1 AQWXGANUJJZTGU-UHFFFAOYSA-N 0.000 claims description 2
- GUBLWTBQTNDNFO-UHFFFAOYSA-N azetidin-1-yl-[3-(4-chloro-5-fluoro-2-methylphenyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-2-yl]methanone Chemical compound Cc1cc(Cl)c(F)cc1-c1c2OCCCn2nc1C(=O)N1CCC1 GUBLWTBQTNDNFO-UHFFFAOYSA-N 0.000 claims description 2
- MONOEYMRTNNARV-UHFFFAOYSA-N azetidin-1-yl-[3-(4-chlorophenyl)-5-methyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-2-yl]methanone Chemical compound CC1CCn2nc(C(=O)N3CCC3)c(c2O1)-c1ccc(Cl)cc1 MONOEYMRTNNARV-UHFFFAOYSA-N 0.000 claims description 2
- BKTUIOVWODWFPG-UHFFFAOYSA-N azetidin-1-yl-[3-(4-chlorophenyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-2-yl]methanone Chemical compound Clc1ccc(cc1)-c1c(nn2CCCOc12)C(=O)N1CCC1 BKTUIOVWODWFPG-UHFFFAOYSA-N 0.000 claims description 2
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims description 2
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 claims description 2
- 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 claims description 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims description 2
- 125000005872 benzooxazolyl group Chemical group 0.000 claims description 2
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims description 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims description 2
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims description 2
- 102100037092 cAMP-specific 3',5'-cyclic phosphodiesterase 4A Human genes 0.000 claims description 2
- 102100029168 cAMP-specific 3',5'-cyclic phosphodiesterase 4B Human genes 0.000 claims description 2
- 102100029169 cAMP-specific 3',5'-cyclic phosphodiesterase 4C Human genes 0.000 claims description 2
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 2
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 claims description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 2
- 125000002541 furyl group Chemical group 0.000 claims description 2
- 125000002632 imidazolidinyl group Chemical group 0.000 claims description 2
- 125000002883 imidazolyl group Chemical group 0.000 claims description 2
- 125000004857 imidazopyridinyl group Chemical group N1C(=NC2=C1C=CC=N2)* 0.000 claims description 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims description 2
- 125000001041 indolyl group Chemical group 0.000 claims description 2
- 230000004054 inflammatory process Effects 0.000 claims description 2
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims description 2
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 2
- 230000001404 mediated effect Effects 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 125000001624 naphthyl group Chemical group 0.000 claims description 2
- 125000000160 oxazolidinyl group Chemical group 0.000 claims description 2
- 125000002971 oxazolyl group Chemical group 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 125000004193 piperazinyl group Chemical group 0.000 claims description 2
- 125000003386 piperidinyl group Chemical group 0.000 claims description 2
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 claims description 2
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 2
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 2
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 2
- 201000000980 schizophrenia Diseases 0.000 claims description 2
- 201000009032 substance abuse Diseases 0.000 claims description 2
- 231100000736 substance abuse Toxicity 0.000 claims description 2
- 125000001424 substituent group Chemical group 0.000 claims description 2
- 125000000335 thiazolyl group Chemical group 0.000 claims description 2
- 125000001544 thienyl group Chemical group 0.000 claims description 2
- 125000001425 triazolyl group Chemical group 0.000 claims description 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 206010013654 Drug abuse Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 208000028017 Psychotic disease Diseases 0.000 claims 1
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- CRKMXHLUZCJURN-UHFFFAOYSA-N azetidin-1-yl-[3-(3-chlorophenyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-2-yl]methanone Chemical compound Clc1cccc(c1)-c1c(nn2CCCOc12)C(=O)N1CCC1 CRKMXHLUZCJURN-UHFFFAOYSA-N 0.000 claims 1
- 230000003542 behavioural effect Effects 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 206010013663 drug dependence Diseases 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000009529 traumatic brain injury Effects 0.000 claims 1
- 0 *N(*)C(c1n[n](CCCO2)c2c1-c1ccccc1)=O Chemical compound *N(*)C(c1n[n](CCCO2)c2c1-c1ccccc1)=O 0.000 description 4
- 238000000034 method Methods 0.000 description 3
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 1
- 125000004566 azetidin-1-yl group Chemical group N1(CCC1)* 0.000 description 1
- WSFSSNUMVMOOMR-BJUDXGSMSA-N methanone Chemical compound O=[11CH2] WSFSSNUMVMOOMR-BJUDXGSMSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662298657P | 2016-02-23 | 2016-02-23 | |
| US62/298,657 | 2016-02-23 | ||
| PCT/IB2017/050844 WO2017145013A1 (en) | 2016-02-23 | 2017-02-15 | 6,7-dihydro-5h-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019505558A JP2019505558A (ja) | 2019-02-28 |
| JP2019505558A5 true JP2019505558A5 (https=) | 2020-03-26 |
| JP6837072B2 JP6837072B2 (ja) | 2021-03-03 |
Family
ID=58347718
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018544154A Active JP6837072B2 (ja) | 2016-02-23 | 2017-02-15 | ６，７−ジヒドロ−５Ｈ−ピラゾロ［５，１−ｂ］［１，３］オキサジン−２−カルボキサミド化合物 |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US10323042B2 (https=) |
| EP (1) | EP3419979B1 (https=) |
| JP (1) | JP6837072B2 (https=) |
| KR (1) | KR102148587B1 (https=) |
| CN (2) | CN113332292A (https=) |
| AU (1) | AU2017223132B2 (https=) |
| BR (1) | BR112018015191B1 (https=) |
| CA (1) | CA3015166C (https=) |
| DK (1) | DK3419979T3 (https=) |
| ES (1) | ES2775674T3 (https=) |
| HU (1) | HUE048658T2 (https=) |
| IL (1) | IL260536B (https=) |
| MX (1) | MX379704B (https=) |
| PL (1) | PL3419979T3 (https=) |
| PT (1) | PT3419979T (https=) |
| RU (1) | RU2719599C2 (https=) |
| SG (1) | SG11201806383TA (https=) |
| WO (1) | WO2017145013A1 (https=) |
| ZA (1) | ZA201804619B (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107787322B (zh) * | 2015-06-17 | 2023-07-07 | 辉瑞大药厂 | 三环化合物以及它们作为磷酸二酯酶抑制剂的用途 |
| WO2018119142A1 (en) | 2016-12-21 | 2018-06-28 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| WO2019169326A1 (en) * | 2018-03-01 | 2019-09-06 | Board Of Regents, The University Of Texas System | Ethanediamine-heterocycle derivatives as inhibitors of protein arginine methyltransferases |
| FI3851436T3 (fi) * | 2018-09-10 | 2024-09-03 | Kaken Pharma Co Ltd | Uusi heteroaromaattinen amidijohdannainen ja sitä sisältävä lääke |
| CA3127357A1 (en) * | 2019-01-23 | 2020-07-30 | Path Therapeutics, Inc. | Methods of treating epilepsy via phosphodiesterase 4 (pde4) inhibition |
| CN121621343A (zh) * | 2026-02-02 | 2026-03-10 | 云南大学 | 一种化合物在防控植物病原真菌尖孢镰刀菌上的应用 |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE239797T1 (de) | 1993-01-25 | 2003-05-15 | Takeda Chemical Industries Ltd | Antikörper gegen beta-amyloid oder derivative davon und seine verwendung |
| DE19709877A1 (de) | 1997-03-11 | 1998-09-17 | Bayer Ag | 1,5-Dihydro-pyrazolo[3,4-d]-pyrimidinon-derivate |
| US8173127B2 (en) | 1997-04-09 | 2012-05-08 | Intellect Neurosciences, Inc. | Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof |
| NZ337765A (en) | 1997-04-09 | 2001-09-28 | Mindset Biopharmaceuticals Usa | Recombinant antibodies having specificity for beta-amyloid N-terminus and C-terminus and use in treating Alzheimer's Disease |
| GB9722520D0 (en) | 1997-10-24 | 1997-12-24 | Pfizer Ltd | Compounds |
| US6905686B1 (en) | 1997-12-02 | 2005-06-14 | Neuralab Limited | Active immunization for treatment of alzheimer's disease |
| TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
| JP2003508401A (ja) * | 1999-08-27 | 2003-03-04 | アボット・ラボラトリーズ | Ｃｏｘ−２阻害薬として有用なスルホニルフェニルピラゾール化合物 |
| WO2001058869A2 (en) | 2000-02-11 | 2001-08-16 | Bristol-Myers Squibb Company | Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators in treating respiratory and non-respiratory diseases |
| DE1257584T1 (de) | 2000-02-24 | 2003-05-28 | Lilly Co Eli | Humanisierte antikörper, die amyloid beta peptid demarkieren |
| DE10045112A1 (de) | 2000-09-11 | 2002-03-21 | Merck Patent Gmbh | Verwendung von Indolderivaten zur Behandlung von Erkrankungen des zentralen Nervensystems |
| CA2427661C (en) | 2000-11-03 | 2013-05-28 | Proteotech, Inc. | Methods of isolating amyloid-inhibiting compounds and use of compounds isolated from uncaria tomentosa and related plants |
| CA2451998A1 (en) | 2001-08-17 | 2003-02-27 | Eli Lilly And Company | Anti-a.beta. antibodies |
| FR2831536A1 (fr) | 2001-10-26 | 2003-05-02 | Aventis Pharma Sa | Nouveaux derives de benzimidazoles, leur procede de preparation, leur application a titre de medicament, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de kdr |
| US20030195205A1 (en) | 2001-11-02 | 2003-10-16 | Pfizer Inc. | PDE9 inhibitors for treating cardiovascular disorders |
| AR039774A1 (es) | 2002-05-01 | 2005-03-02 | Wyeth Corp | 6-alquiliden-penems biciclicos como inhibidores de beta-lactamasas |
| US20040132708A1 (en) | 2002-05-01 | 2004-07-08 | Wyeth | Process for preparing 6-alkylidene penem derivatives |
| DE10238723A1 (de) | 2002-08-23 | 2004-03-11 | Bayer Ag | Phenyl-substituierte Pyrazolyprimidine |
| DE10238724A1 (de) | 2002-08-23 | 2004-03-04 | Bayer Ag | Alkyl-substituierte Pyrazolpyrimidine |
| US20040146512A1 (en) | 2002-10-09 | 2004-07-29 | Arnon Rosenthal | Methods of treating Alzheimer's disease using antibodies directed against amyloid beta peptide and compositions thereof |
| US20040220186A1 (en) | 2003-04-30 | 2004-11-04 | Pfizer Inc. | PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease |
| BRPI0410630A (pt) | 2003-06-19 | 2006-06-13 | Pfizer Prod Inc | antagonista de nk1 |
| EP1666061A1 (en) | 2003-09-09 | 2006-06-07 | Takeda Pharmaceutical Company Limited | Use of antibody |
| GB0327319D0 (en) | 2003-11-24 | 2003-12-24 | Pfizer Ltd | Novel pharmaceuticals |
| EP1720847A1 (en) | 2004-02-02 | 2006-11-15 | Pfizer Products Incorporated | Histamine-3 receptor modulators |
| US7456164B2 (en) | 2004-05-07 | 2008-11-25 | Pfizer, Inc | 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands |
| EP1595881A1 (en) | 2004-05-12 | 2005-11-16 | Pfizer Limited | Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands |
| EP1765830B1 (en) * | 2004-07-01 | 2010-09-22 | Merck Sharp & Dohme Corp. | Mitotic kinesin inhibitors |
| MX2007000998A (es) | 2004-07-30 | 2007-07-11 | Rinat Neuroscience Corp | Anticuerpos dirigidos peptido beta-amiloide y procedimientos que usan los mismos. |
| GB0423356D0 (en) | 2004-10-21 | 2004-11-24 | Merck Sharp & Dohme | Therapeutic agents |
| US20090074775A1 (en) | 2004-12-22 | 2009-03-19 | David Michael Holtzman | Use Of Anti-AB Antibody To Treat Traumatic Brain Injury |
| UY29504A1 (es) | 2005-04-29 | 2006-10-31 | Rinat Neuroscience Corp | Anticuerpos dirigidos contra el péptido amiloide beta y métodos que utilizan los mismos. |
| CA2608018C (en) | 2005-05-12 | 2010-07-13 | Pfizer Inc. | Anhydrous crystalline forms of n-[1-(2-ethoxyethyl)-5-(n-ethyl-n-methylamino)-7-(4-methylpyridin-2-yl-amino)-1h-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide |
| WO2006126083A1 (en) | 2005-05-24 | 2006-11-30 | Pharmacia & Upjohn Company Llc | Pyridine [3 , 4-b] pyrazinone compounds as pde-5 inhibitors |
| WO2006126081A2 (en) | 2005-05-24 | 2006-11-30 | Pharmacia & Upjohn Company Llc | Pyridino [2 , 3-b] pyrazinones as pde-5 inhibitors |
| CA2608672A1 (en) | 2005-05-24 | 2006-11-30 | Pharmacia & Upjohn Company Llc | Pyridine [3,4-b] pyrazinones as pde-5 inhibitors |
| TW200716102A (en) | 2005-06-01 | 2007-05-01 | Wyeth Corp | Bicyclic 6-alkylidene-penems as class-D β -lactamases inhibitors |
| DE602006018301D1 (de) | 2005-06-22 | 2010-12-30 | Pfizer Prod Inc | Histamin-3-rezeptorantagonisten |
| US8158673B2 (en) | 2005-10-27 | 2012-04-17 | Pfizer Inc. | Histamine-3 receptor antagonists |
| EP1779848A1 (en) * | 2005-10-28 | 2007-05-02 | Nikem Research S.R.L. | V-ATPase inhibitors for the treatment of inflammatory and autoimmune diseases |
| CA2624625A1 (en) | 2005-11-04 | 2007-05-10 | Pfizer Limited | Tetrahydronaphthyridine derivative |
| WO2007063385A2 (en) | 2005-12-01 | 2007-06-07 | Pfizer Products Inc. | Spirocyclic amine histamine-3 receptor antagonists |
| WO2007069053A1 (en) | 2005-12-14 | 2007-06-21 | Pfizer Products Inc. | Benzimidazole antagonists of the h-3 receptor |
| WO2007088450A2 (en) | 2006-02-01 | 2007-08-09 | Pfizer Products Inc. | Chromane antagonist of the h-3 receptor |
| WO2007088462A1 (en) | 2006-02-01 | 2007-08-09 | Pfizer Products Inc. | Spirochromane antagonists of the h-3 receptor |
| WO2007099423A1 (en) | 2006-03-02 | 2007-09-07 | Pfizer Products Inc. | 1-pyrrolidine indane derivatives as histamine-3 receptor antagonists |
| AR059955A1 (es) * | 2006-03-09 | 2008-05-14 | Eisai R&D Man Co Ltd | Compuestos policiclicos no peptidicos, medicamentos que los contienen, y usos para prevenir o tratar enfermedades causadas por la produccion de beta amiloide |
| CA2643055A1 (en) | 2006-03-13 | 2007-09-20 | Pfizer Products Inc. | Tetralines antagonists of the h-3 receptor |
| AU2007242555B2 (en) | 2006-04-21 | 2010-12-16 | Pfizer Products Inc. | Pyridine[3,4-b]pyrazinones |
| WO2007138431A2 (en) | 2006-05-30 | 2007-12-06 | Pfizer Products Inc. | Azabicyclic ether histamine-3 antagonists |
| JP4585610B2 (ja) | 2007-01-22 | 2010-11-24 | ファイザー・プロダクツ・インク | 治療用化合物のトシル酸塩およびその医薬組成物 |
| MX2010012492A (es) * | 2008-05-27 | 2010-12-21 | Astrazeneca Ab | Derivados de fenoxipiridinilamida y su uso en el tratamiento de estados de enfermedad mediados por fosfodiesterasa 4. |
| WO2010144416A1 (en) * | 2009-06-08 | 2010-12-16 | Gaeta Federico C A | SUBSTITUTED PYRAZOLO [1,5-a] PYRIDINE COMPOUNDS HAVING MULTI-TARGET ACTIVITY |
| TWI532725B (zh) | 2010-01-26 | 2016-05-11 | 賽諾菲阿凡提斯公司 | 經氧取代之３－雜芳醯基胺基－丙酸衍生物及其作為藥物之用途 |
| BR112015019276A2 (pt) * | 2013-02-19 | 2017-07-18 | Pfizer | compostos de azabenzimidazol como inibidores de isoenzimas de pde4 para o tratamento de distúrbios do snc e outros distúrbios |
| JP6568855B2 (ja) * | 2014-07-30 | 2019-08-28 | 持田製薬株式会社 | ピラゾール誘導体の製造方法 |
| MD20170011A2 (ro) * | 2014-08-06 | 2017-08-31 | Pfizer Inc. | Compuşi imidazopiridazinici |
-
2017
- 2017-02-15 CN CN202110445183.8A patent/CN113332292A/zh active Pending
- 2017-02-15 PL PL17711330T patent/PL3419979T3/pl unknown
- 2017-02-15 CA CA3015166A patent/CA3015166C/en active Active
- 2017-02-15 PT PT177113305T patent/PT3419979T/pt unknown
- 2017-02-15 DK DK17711330.5T patent/DK3419979T3/da active
- 2017-02-15 JP JP2018544154A patent/JP6837072B2/ja active Active
- 2017-02-15 BR BR112018015191-2A patent/BR112018015191B1/pt active IP Right Grant
- 2017-02-15 MX MX2018010177A patent/MX379704B/es unknown
- 2017-02-15 WO PCT/IB2017/050844 patent/WO2017145013A1/en not_active Ceased
- 2017-02-15 RU RU2018128781A patent/RU2719599C2/ru active
- 2017-02-15 AU AU2017223132A patent/AU2017223132B2/en active Active
- 2017-02-15 KR KR1020187023853A patent/KR102148587B1/ko active Active
- 2017-02-15 CN CN201780013020.4A patent/CN108699080B/zh active Active
- 2017-02-15 US US16/074,290 patent/US10323042B2/en active Active
- 2017-02-15 ES ES17711330T patent/ES2775674T3/es active Active
- 2017-02-15 HU HUE17711330A patent/HUE048658T2/hu unknown
- 2017-02-15 SG SG11201806383TA patent/SG11201806383TA/en unknown
- 2017-02-15 EP EP17711330.5A patent/EP3419979B1/en active Active
-
2018
- 2018-07-11 IL IL260536A patent/IL260536B/en active IP Right Grant
- 2018-07-11 ZA ZA2018/04619A patent/ZA201804619B/en unknown
-
2019
- 2019-05-31 US US16/427,627 patent/US10738063B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019505558A5 (https=) | ||
| EP3027604B1 (en) | Novel quinazolinones as bromodomain inhibitors | |
| ES2346674T3 (es) | Compuestos heteroaromaticos de quinolina y su uso como inhibidores de pde10. | |
| JP2018519323A5 (https=) | ||
| JP2017508766A5 (https=) | ||
| JP2019505541A5 (https=) | ||
| HRP20170112T1 (hr) | Supstituirani spojevi piridin-2-karboksamida kao kinazni inhibitori signalne regulacije apoptoze | |
| RU2018128781A (ru) | Соединения 6, 7-дигидро-5H-пиразоло[5,1-b][1,3]оксазин-2-карбоксамида | |
| HRP20150082T1 (hr) | Derivati pirazolo piridina kao inhibitori nadph oksidaze | |
| JP2019530695A5 (https=) | ||
| EP3209665B1 (en) | Substituted pyrrolotriazine amine compounds as pi3k inhibitors | |
| JP2014037426A5 (https=) | ||
| JP2006520805A5 (https=) | ||
| JP2017530999A5 (https=) | ||
| JP2017525757A5 (https=) | ||
| JP2017512786A5 (https=) | ||
| JP2016507581A5 (https=) | ||
| JP2014526501A5 (https=) | ||
| RU2014106020A (ru) | Ингибиторы втк | |
| RU2016141647A (ru) | ИНГИБИТОРЫ TrkA КИНАЗЫ, ОСНОВАННЫЕ НА НИХ КОМПОЗИЦИИ И СПОСОБЫ | |
| JP2017523223A5 (https=) | ||
| JP2016503785A5 (https=) | ||
| AU2018346712A1 (en) | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD | |
| JP2015503609A5 (https=) | ||
| CA2628844A1 (en) | Pyrazole derivatives and their medical use |